The Angiogenesis Foundation, One Broadway, 14th Floor, Cambridge, MA 02142, USA.
J Oncol. 2012;2012:879623. doi: 10.1155/2012/879623. Epub 2011 Sep 29.
Between 2000 and 2050, the number of new cancer patients diagnosed annually is expected to double, with an accompanying increase in treatment costs of more than $80 billion over just the next decade. Efficacious strategies for cancer prevention will therefore be vital for improving patients' quality of life and reducing healthcare costs. Judah Folkman first proposed antiangiogenesis as a strategy for preventing dormant microtumors from progressing to invasive cancer. Although antiangiogenic drugs are now available for many advanced malignancies (colorectal, lung, breast, kidney, liver, brain, thyroid, neuroendocrine, multiple myeloma, myelodysplastic syndrome), cost and toxicity considerations preclude their broad use for cancer prevention. Potent antiangiogenic molecules have now been identified in dietary sources, suggesting that a rationally designed antiangiogenic diet could provide a safe, widely available, and novel strategy for preventing cancer. This paper presents the scientific, epidemiologic, and clinical evidence supporting the role of an antiangiogenic diet for cancer prevention.
预计在 2000 年至 2050 年期间，每年新诊断出的癌症患者数量将增加一倍，仅在未来十年内，治疗成本就将增加 800 多亿美元。因此，有效的癌症预防策略对于提高患者的生活质量和降低医疗成本至关重要。 Judah Folkman 首次提出抗血管生成作为预防休眠微肿瘤进展为侵袭性癌症的策略。尽管现在有许多晚期恶性肿瘤（结直肠癌、肺癌、乳腺癌、肾癌、肝癌、脑癌、甲状腺癌、神经内分泌癌、多发性骨髓瘤、骨髓增生异常综合征）可使用抗血管生成药物，但成本和毒性考虑因素排除了它们在癌症预防中的广泛应用。现在已经在饮食来源中发现了有效的抗血管生成分子，这表明合理设计的抗血管生成饮食可能是一种安全、广泛可用的预防癌症的新策略。本文介绍了支持抗血管生成饮食在癌症预防中的作用的科学、流行病学和临床证据。
